Oxidative pentose phosphate pathway inhibition is a key determinant of antimalarial induced cancer cell death

Oncogene

Volumn 35, Issue 22, 2016, Pages 2913-2922

  Salas, E ^a   Roy, S ^a   Marsh, T ^a   Rubin, B ^b   Debnath, J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHLOROQUINE; GLUCOSE 6 PHOSPHATE DEHYDROGENASE; K RAS PROTEIN; MEPACRINE; PROTEIN P53; REACTIVE OXYGEN METABOLITE; ANTIMALARIAL AGENT; KRAS PROTEIN, HUMAN; PROTEIN P21;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; AUTOPHAGOSOME; AUTOPHAGY; CANCER INHIBITION; CANCER SURVIVAL; CELL PROLIFERATION; CONTROLLED STUDY; DRUG CYTOTOXICITY; ENZYME ACTIVITY; GENE TARGETING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NON SMALL CELL LUNG CANCER; NONHUMAN; PENTOSE PHOSPHATE CYCLE; PHENOTYPE; PRIORITY JOURNAL; RNAI THERAPEUTICS; TREATMENT RESPONSE; TUMOR XENOGRAFT; DRUG EFFECTS; GENETICS; LUNG TUMOR; METABOLISM; MUTATION; OXIDATION REDUCTION REACTION; PATHOLOGY; TUMOR CELL LINE;

ANTIMALARIALS; APOPTOSIS; AUTOPHAGY; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL PROLIFERATION; CHLOROQUINE; HUMANS; LUNG NEOPLASMS; MUTATION; OXIDATION-REDUCTION; PENTOSE PHOSPHATE PATHWAY; PROTO-ONCOGENE PROTEINS P21(RAS); TUMOR SUPPRESSOR PROTEIN P53;

EID: 84973316188     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2015.348     Document Type: Article

References (35)

1. Murrow L, Debnath J. Autophagy as a stress-response and quality-control mechanism: implications for cell injury and human disease. Annu Rev Pathol 2013; 8: 105-137.
2. Kimmelman AC. The dynamic nature of autophagy in cancer. Genes Dev 2011; 25: 1999-2010.
3. Amaravadi RK, Lippincott-Schwartz J, Yin XM, Weiss WA, Takebe N, Timmer W et al. Principles and current strategies for targeting autophagy for cancer treatment. Clin Cancer Res 2011; 17: 654-666.
4. Barnard RA, Wittenburg LA, Amaravadi RK, Gustafson DL, Thorburn A, Thamm DH. Phase I clinical trial and pharmacodynamic evaluation of combination hydroxychloroquine and doxorubicin treatment in pet dogs treated for spontaneously occurring lymphoma. Autophagy 2014; 10: 1415-1425.
5. Mahalingam D, Mita M, Sarantopoulos J, Wood L, Amaravadi RK, Davis LE et al. Combined autophagy and HDAC inhibition: A phase I safety, tolerability, pharmacokinetic, and pharmacodynamic analysis of hydroxychloroquine in combination with the HDAC inhibitor vorinostat in patients with advanced solid tumors. Autophagy 2014; 10: 1403-1414.
6. Rangwala R, Chang YC, Hu J, Algazy KM, Evans TL, Fecher LA et al. Combined MTOR and autophagy inhibition: phase I trial of hydroxychloroquine and temsirolimus in patients with advanced solid tumors and melanoma. Autophagy 2014; 10: 1391-1402.
7. Rangwala R, Leone R, Chang YC, Fecher LA, Schuchter LM, Kramer A et al. Phase I trial of hydroxychloroquine with dose-intense temozolomide in patients with advanced solid tumors and melanoma. Autophagy 2014; 10: 1369-1379.
8. Rosenfeld MR, Ye X, Supko JG, Desideri S, Grossman SA, Brem S et al. A phase I/II trial of hydroxychloroquine in conjunction with radiation therapy and concurrent and adjuvant temozolomide in patients with newly diagnosed glioblastoma multiforme. Autophagy 2014; 10: 1359-1368.
9. Vogl DT, Stadtmauer EA, Tan KS, Heitjan DF, Davis LE, Pontiggia L et al. Combined autophagy and proteasome inhibition: A phase 1 trial of hydroxychloroquine and bortezomib in patients with relapsed/refractory myeloma. Autophagy 2014; 10: 1380-1390.
10. Wolpin BM, Rubinson DA, Wang X, Chan JA, Cleary JM, Enzinger PC et al. Phase II and pharmacodynamic study of autophagy inhibition using hydroxychloroquine in patients with metastatic pancreatic adenocarcinoma. Oncologist 2014; 19: 637-638.
11. Maycotte P, Aryal S, Cummings CT, Thorburn J, Morgan MJ, Thorburn A. Chloroquine sensitizes breast cancer cells to chemotherapy independent of autophagy. Autophagy 2012; 8: 200-212.
12. Maes H, Kuchnio A, Peric A, Moens S, Nys K, De Bock K et al. Tumor vessel normalization by chloroquine independent of autophagy. Cancer Cell 2014; 26: 190-206.
13. Gallant JN, Allen JE, Smith CD, Dicker DT, Wang W, Dolloff NG et al. Quinacrine synergizes with 5-fluorouracil and other therapies in colorectal cancer. Cancer Biol Ther 2011; 12: 239-251.
14. Gurova KV, Hill JE, Guo C, Prokvolit A, Burdelya LG, Samoylova E et al. Small molecules that reactivate p53 in renal cell carcinoma reveal a NF-kappaBdependent mechanism of p53 suppression in tumors. Proc Natl Acad Sci USA 2005; 102: 17448-17453.
15. Ehsanian R, Van Waes C, Feller SM. Beyond DNA binding-A review of the potential mechanisms mediating quinacrine's therapeutic activities in parasitic infections, inflammation, and cancers. Cell Commun Signal 2011; 9: 13.
16. Gupta A, Roy S, Lazar AJ, Wang WL, McAuliffe JC, Reynoso D et al. Autophagy inhibition and antimalarials promote cell death in gastrointestinal stromal tumor (GIST). Proc Natl Acad Sci USA 2010; 107: 14333-14338.
17. Geng Y, Kohli L, Klocke BJ, Roth KA. Chloroquine-induced autophagic vacuole accumulation and cell death in glioma cells is p53 independent. Neuro Oncol 2010; 12: 473-481.
18. Guo JY, Chen HY, Mathew R, Fan J, Strohecker AM, Karsli-Uzunbas G et al. Activated Ras requires autophagy to maintain oxidative metabolism and tumorigenesis. Genes Dev 2011; 25: 460-470.
19. Guo JY, Karsli-Uzunbas G, Mathew R, Aisner SC, Kamphorst JJ, Strohecker AM et al. Autophagy suppresses progression of K-ras-induced lung tumors to oncocytomas and maintains lipid homeostasis. Genes Dev 2013; 27: 1447-1461.
20. Lock R, Roy S, Kenific CM, Su JS, Salas E, Ronen SM et al. Autophagy facilitates glycolysis during Ras-mediated oncogenic transformation. Mol Biol Cell 2011; 22: 165-178.
21. Yang S, Wang X, Contino G, Liesa M, Sahin E, Ying H et al. Pancreatic cancers require autophagy for tumor growth. Genes Dev 2011; 25: 717-729.
22. Lock R, Kenific CM, Leidal AM, Salas E, Debnath J. Autophagy-dependent production of secreted factors facilitates oncogenic RAS-driven invasion. Cancer Discov 2014; 4: 466-479.
23. Klionsky DJ, Abdalla FC, Abeliovich H, Abraham RT, Acevedo-Arozena A, Adeli K et al. Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy 2012; 8: 445-544.
24. Buchakjian MR, Kornbluth S. The engine driving the ship: metabolic steering of cell proliferation and death. Nat Rev Mol Cell Biol 2010; 11: 715-727.
25. Schafer ZT, Grassian AR, Song L, Jiang Z, Gerhart-Hines Z, Irie HY et al. Antioxidant and oncogene rescue of metabolic defects caused by loss of matrix attachment. Nature 2009; 461: 109-113.
26. Bakkenist CJ, Kastan MB. DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation. Nature 2003; 421: 499-506.
27. Maclean KH, Dorsey FC, Cleveland JL, Kastan MB. Targeting lysosomal degradation induces p53-dependent cell death and prevents cancer in mouse models of lymphomagenesis. J Clin Invest 2008; 118: 79-88.
28. Vousden KH, Ryan KM. p53 and metabolism. Nat Rev Cancer 2009; 9: 691-700.
29. Jiang P, Du W, Wang X, Mancuso A, Gao X, Wu M et al. p53 regulates biosynthesis through direct inactivation of glucose-6-phosphate dehydrogenase. Nat Cell Biol 2011; 13: 310-316.
30. Maycotte P, Gearheart CM, Barnard R, Aryal S, Mulcahy Levy JM, Fosmire SP et al. STAT3-mediated autophagy dependence identifies subtypes of breast cancer where autophagy inhibition can be efficacious. Cancer Res 2014; 74: 2579-2590.
31. Karsli-Uzunbas G, Guo JY, Price S, Teng X, Laddha SV, Khor S et al. Autophagy is required for glucose homeostasis and lung tumor maintenance. Cancer Discov 2014; 4: 914-927.
32. Rosenfeldt MT, O'Prey J, Morton JP, Nixon C, MacKay G, Mrowinska A et al. p53 status determines the role of autophagy in pancreatic tumour development. Nature 2013; 504: 296-300.
33. Yang A, Rajeshkumar NV, Wang X, Yabuuchi S, Alexander BM, Chu GC et al. Autophagy is critical for pancreatic tumor growth and progression in tumors with p53 alterations. Cancer Discov 2014; 4: 905-913.
34. McAfee Q, Zhang Z, Samanta A, Levi SM, Ma XH, Piao S et al. Autophagy inhibitor Lys05 has single-Agent antitumor activity and reproduces the phenotype of a genetic autophagy deficiency. Proc Natl Acad Sci USA 2012; 109: 8253-8258.
35. Fung C, Lock R, Gao S, Salas E, Debnath J. Induction of autophagy during extracellular matrix detachment promotes cell survival. Mol Biol Cell 2008; 19: 797-806.